Annals of Surgical Oncology, Vol 7, Issue 2 160-165, Copyright © 2000 by Society of Surgical Oncology

ARTICLES

Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma

J. E. Gershenwald, P. F. Mansfield, J. E. Lee and M. I. Ross
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

BACKGROUND: Historically, patients with thick (> or =4 mm) primary melanoma have not been considered candidates for elective lymph node dissection, because their risk for occult distant disease is significant. Sentinel lymph node (SLN) biopsy offers an alternative approach to assess disease in the regional nodal basin, but no studies have specifically addressed the role for this technique in patients with thick melanoma. Although adjuvant therapy benefits patients who develop nodal metastases, data that supports its routine use in all patients with thick melanoma is both limited and controversial. This study was performed to determine whether pathological status of the SLN is an important risk factor in this heterogeneous group and, thus, provides a rationale for SLN biopsy. METHODS: The records of 131 patients with primary cutaneous melanoma whose primary tumors were at least 4 mm thick and who underwent lymphatic mapping and SLN biopsy were reviewed. Several known prognostic factors, i.e., tumor thickness, ulceration, Clark level, location, sex, as well as SLN pathological status were analyzed with respect to disease-free and overall survival. RESULTS: Lymphatic mapping and SLN biopsy was successful in 126 (96%) of 131 patients who underwent the procedure. In 49 patients (39%), the SLN biopsy was positive by conventional histology, although it was negative in 77 patients (61%). The median follow-up was 3 years. Although presence of ulceration and SLN status were independent prognostic factors with respect to disease-free and overall survival, SLN status was the most powerful predictor of overall survival by univariate and multivariate analyses. CONCLUSIONS: Lymphatic mapping and SLN biopsy is a highly accurate method of staging lymph node basins at risk for regional metastases in patients with thick melanoma and identifies those patients who may benefit from earlier lymphadenectomy as well as patients with a more favorable prognosis. Pathological status of the SLN in these patients with clinically negative nodes is the most important prognostic factor for survival and is essential to establish stratification criteria for future adjuvant trials in this high-risk group.

This article has been cited by other articles:

				Z. I. Nowecki, P. Rutkowski, and W. Michej The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2-pT3) Ann. Surg. Oncol., August 1, 2008; 15(8): 2223 - 2234. [Abstract] [Full Text] [PDF]

				Z. I. Nowecki, P. Rutkowski, A. Nasierowska-Guttmejer, and W. Ruka Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma Ann. Surg. Oncol., December 1, 2006; 13(12): 1655 - 1663. [Abstract] [Full Text] [PDF]

				C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al. Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma J. Clin. Oncol., June 20, 2006; 24(18): 2849 - 2857. [Abstract] [Full Text] [PDF]

				M. I. Ross Early-stage melanoma: staging criteria and prognostic modeling. Clin. Cancer Res., April 1, 2006; 12(7): 2312s - 2319s. [Abstract] [Full Text] [PDF]

				T. M. Pawlik, M. I. Ross, and J. E. Gershenwald Lymphatic Mapping in the Molecular Era Ann. Surg. Oncol., April 1, 2004; 11(4): 362 - 374. [Full Text] [PDF]

				V. K. Sondak, J. M. G. Taylor, M. S. Sabel, Y. Wang, L. Lowe, A. C. Grover, A. E. Chang, A. M. Yahanda, J. Moon, and T. M. Johnson Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model Ann. Surg. Oncol., March 1, 2004; 11(3): 247 - 258. [Abstract] [Full Text] [PDF]

				C. Caraco, E. Celentano, S. Lastoria, G. Botti, P. A. Ascierto, and N. Mozzillo Sentinel Lymph Node Biopsy Does not Change Melanoma-Specific Survival Among Patients with Breslow Thickness Greater than Four Millimeters Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 198S - 202S. [Abstract] [Full Text] [PDF]

				D. L. Rousseau Jr, M. I. Ross, M. M. Johnson, V. G. Prieto, J. E. Lee, P. F. Mansfield, and J. E. Gershenwald Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients Ann. Surg. Oncol., June 1, 2003; 10(5): 569 - 574. [Abstract] [Full Text] [PDF]

				G. W. Carlson, D. R. Murray, A. Hestley, C. A. Staley, R. H. Lyles, and C. Cohen Sentinel Lymph Node Mapping for Thick (>=4-mm) Melanoma: Should We Be Doing It? Ann. Surg. Oncol., May 1, 2003; 10(4): 408 - 415. [Abstract] [Full Text] [PDF]

				M. H. Chung, R. K. Gupta, E. Hsueh, R. Essner, W. Ye, R. Yee, and D. L. Morton Humoral Immune Response to a Therapeutic Polyvalent Cancer Vaccine After Complete Resection of Thick Primary Melanoma and Sentinel Lymphadenectomy J. Clin. Oncol., January 15, 2003; 21(2): 313 - 319. [Abstract] [Full Text] [PDF]

				J. F. Thompson and H. M. Shaw The Prognosis of Patients With Thick Primary Melanomas: Is Regional Lymph Node Status Relevant, and Does Removing Positive Regional Nodes Influence Outcome? Ann. Surg. Oncol., October 1, 2002; 9(8): 719 - 722. [Full Text] [PDF]

				R. Essner, M. H. Chung, R. Bleicher, E. Hsueh, L. Wanek, and D. L. Morton Prognostic Implications of Thick (>=4-mm) Melanoma in the Era of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy Ann. Surg. Oncol., October 1, 2002; 9(8): 754 - 761. [Abstract] [Full Text] [PDF]

				C. R. Ferrone, K. S. Panageas, K. Busam, M. S. Brady, and D. G. Coit Multivariate Prognostic Model for Patients With Thick Cutaneous Melanoma: Importance of Sentinel Lymph Node Status Ann. Surg. Oncol., August 1, 2002; 9(7): 637 - 645. [Abstract] [Full Text] [PDF]

				G. Mariani, M. Gipponi, L. Moresco, G. Villa, M. Bartolomei, G. Mazzarol, M. C. Bagnara, A. Romanini, F. Cafiero, G. Paganelli, et al. Radioguided Sentinel Lymph Node Biopsy in Malignant Cutaneous Melanoma* J. Nucl. Med., June 1, 2002; 43(6): 811 - 827. [Abstract] [Full Text] [PDF]

				L. Kretschmer, C. Neumann, B. Coldiron, S. Dinehart, J. M. Kirkwood, S. S. Agarwala, J. Ibrahim, J. Manola, V. K. Sondak, M. S. Ernstoff, et al. Sentinel-Node Technique Will Change the Design of Clinical Trials in Malignant Melanoma J. Clin. Oncol., April 15, 2002; 20(8): 2208 - 2210. [Full Text] [PDF]

				M. H. Chung, R. K. Gupta, R. Essner, W. Ye, R. Yee, and D. L. Morton Serum TA90 Immune Complex Assay Can Predict Outcome After Resection of Thick (>=4 mm) Primary Melanoma and Sentinel Lymphadenectomy Ann. Surg. Oncol., March 1, 2002; 9(2): 120 - 126. [Abstract] [Full Text] [PDF]

				G. I. Salti, A. Kansagra, M. A. Warso, S. G. Ronan, and T. K. Das Gupta Clinical Node-Negative Thick Melanoma Arch Surg, March 1, 2002; 137(3): 291 - 295. [Abstract] [Full Text] [PDF]

				R. W. Dubois, S. M. Swetter, M. Atkins, K. McMasters, R. Halbert, S. J. Miller, R. Shiell, and J. Kirkwood Developing Indications for the Use of Sentinel Lymph Node Biopsy and Adjuvant High-Dose Interferon Alfa-2b in Melanoma Arch Dermatol, September 1, 2001; 137(9): 1217 - 1224. [Abstract] [Full Text] [PDF]

				C. M. Balch, A. C. Buzaid, S.-J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr, J. M. Kirkwood, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma J. Clin. Oncol., August 15, 2001; 19(16): 3635 - 3648. [Abstract] [Full Text] [PDF]